Meningococcal Polysaccharide Vaccine Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Meningococcal Meningitis Prophylaxis

0.5 mL subcutaneously once. Protective antibody levels may be achieved in 10 to 14 days after vaccination.

Usual Pediatric Dose for Meningococcal Meningitis Prophylaxis

The safety and efficacy of meningococcal meningitis prophylaxis vaccine in children less than 2 years has not been established.

2 years or older:
0.5 mL subcutaneously once. Protective antibody levels may be achieved in 10 to 14 days after vaccination.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dialysis

Data not available

Other Comments

Revaccination with meningococcal conjugate vaccine (Menactra) is indicated in patients who were previously vaccinated with meningococcal polysaccharide vaccine (Menomune) or meningococcal conjugate vaccine (Menactra) and remain at an increased risk for meningococcal infection. Persons at high risk for infection (those with prolonged increased risk for meningococcal disease) have increased susceptibility, such as persistent complement component deficiencies; persons with anatomic or functional asplenia; and persons with prolonged exposure, including lab workers or travelers to hyperendemic or epidemic areas. Revaccination is also indicated for college freshmen living in dormitories if they received meningococcal polysaccharide vaccine 5 or more years previously. Persons who remain at high risk should then be revaccinated every 5 years. Revaccination with meningococcal conjugate vaccine (Menactra) is not indicated for persons living in dormitories if on campus housing is their only risk factor; however, revaccination is indicated for college freshmen living in dormitories if they received meningococcal polysaccharide vaccine (Menomune) 5 or more years previously.

ACIP Recommendations:
Children less than 2 years: Not usually recommended. Two doses (0.5 mL/dose), 3 months apart, may be considered in children 3 to 18 months to elicit short-term protection against serogroup A disease. A single dose may be considered in children 19 to 23 months (CDC, 2005).
Children 2 years and older and Adults 55 years or younger: use is not generally recommended; meningococcal conjugate vaccine is preferred (CDC, 2011). If meningococcal conjugate vaccine is unavailable, meningococcal polysaccharide vaccine is an acceptable alternative (CDC, 2005). Persons at prolonged increased risk for meningococcal disease should be revaccinated with meningococcal conjugate vaccine (CDC, 2009).
Adults over 55 years: meningococcal polysaccharide vaccine is preferred in this population (CDC, 2005).

Hide
(web2)